aflibercept ophthalmic (Eylea)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Dosage

  • 2 mg (0.05 mL) every 4 weeks for 3 months, then 2 mg (0.05 mL) every 8 weeks

Solution: 40 mg/mL solution for intravitreal injection in a single-use vial

Adverse effects

Mechanism of action

Notes

More general terms

References

  1. FDA NEWS RELEASE: Nov. 18, 2011 FDA approves Eylea for eye disorder in older people http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280601.htm
  2. The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692915 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1414264
    Martin DF, Maguire MG. Treatment Choice for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. [Epub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692914 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1500351
  3. aflibercept (Eylea) prescribing information http://www.regeneron.com/docs/eylea-fpi.pdf